Clinical trial · Observational
Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients
Social Media-based Patient Education and Active Self-report on Incidence and Outcomes of Adverse Events in Natural Killer/T-cell Lymphoma (NK/TCL) Patients
NCT03079544CI-TRIAL-00053866completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extranodal NK-T-Cell Lymphoma, Nasal Type | Extranodal NK-/T-Cell Lymphoma, Nasal Type | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-Asparaginase or or Pegaspargase containing chemotherapy | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 2-year
- description
- The overall survial time of patients will be measured since the initiation of treatment to death of any reason.
Secondary outcomes (2)
- measure
- Treatment-Related Adverse Events as Assessed by CTCAE v4.0
- timeFrame
- Day 1 of each course of chemotherapy and radiotherapy then every 3 months for 2 years
- description
- Chemotherapy-related and radiotherapy-related toxicities and adverse events will be collected and graded by NCI CTCAE v4.0 criteria.
- measure
- Progression free survival
- timeFrame
- 2-year
- description
- Progression free survival time is defined as the time from the initiation of treatment to the date on which disease "progresses" or the date on which the patient dies, from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type based on WHO 2008 classification of tumors of haematopoietic and lymphoid tissue. * Treated with at least one cycle of L-asparaginas or Pegaspargase based chemotherapy. * Signed Informed consent. Exclusion Criteria: * patients who are enrolled in any other clinical trials. * Relapsed patients who were initially treated with non-L-asparaginas or non-pegaspargase based regimens.
References
Publications (0)
Data not yet available
No reference posted for this study.